Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation

DNA methyltransferase inhibitor (DNMTi) treatments have been used for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and have shown promising beneficial effects in some other types of cancers. Here, we demonstrate that the transcriptional repressor ZBTB38 is a critic...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchal, Claire, de Dieuleveult, Maud, Saint-Ruf, Claude, Guinot, Nadège, Ferry, Laure, Olalla Saad, Sara T., Lazarini, Mariana, Defossez, Pierre-Antoine, Miotto, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182000/
https://www.ncbi.nlm.nih.gov/pubmed/30310057
http://dx.doi.org/10.1038/s41389-018-0092-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182000/
https://www.ncbi.nlm.nih.gov/pubmed/30310057
http://dx.doi.org/10.1038/s41389-018-0092-0

Ejemplares similares